Sarepta downgraded to Hold from from Buy at Canaccord

theflyonthewall.com

Canaccord downgraded Sarepta citing near-term uncertainty around the company's talks with the FDA. The firm keeps a $20 price target for shares.

Rates

View Comments (0)